Second Sight Medical Products (EYES) Stock Rises Today on Positive Clinical Results

Posted: Published on April 9th, 2015

This post was added by Dr. Richardson

NEW YORK (TheStreet) -- Second Sight Medical Products (EYES) shares are up 14.6% to $14.47 in trading on Wednesday after the implantable visual prosthetic manufacturer announced the first successful implant of a mechanical model of itsOrion I Visual Cortical Prosthesis in an animal study.

Fully functional prototypes of Orion I are expected to be completed later this year. Active animal implants are scheduled to begin by the first quarter of2016, and human trials arescheduled for the first quarter of 2017.

"This is a major milestone not only for the company but, more importantly, those affected by virtually all forms of blindness. Following the success of Argus II in patients with Retinitis Pigmentosa, we are looking forward to extending the hope of restoring some useful vision to nearly all blind individuals with the Orion I," said CEO Dr. Robert Greenberg

Second Sight stock isrising on heavy volume with 4.6 million shares being traded so far, ahead of its three month daily average of 1.4 million shares. EYES data by YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015

Read the rest here:
Second Sight Medical Products (EYES) Stock Rises Today on Positive Clinical Results

Related Posts
This entry was posted in Retinitis Pigmentosa. Bookmark the permalink.

Comments are closed.